Over the last two decades, the University Research sector has witnessed an explosion in drug discovery activities that before have been the domain of the traditional pharmaceutical companies. This shift has been fueled by the changing landscape of the pharmaceutical industry. As pressure mounts on these companies to increase the return on publicly traded investments, hard-line decisions are being made about which therapies to pursue. Unfortunately for the patient, more therapies are being left behind that don’t have large or immediate promise.
Public and private research institutions have, to some extent, filled the gap through traditional grant funded research. The more savvy institutions have leveraged those research efforts into increased royalty and patent income streams, but at best, have produced mixed revenue levels. Public or private research universities find it daunting to navigate through the treacherous waters of drug development and delivery. The barriers to entry are high, and in many cases nearly impossible to surmount due to factors ranging from insufficient funding to lack of training in the intricacies of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP). Our goal here is to provide a means by which new therapeutic discoveries can be delivered effectively and safely to the market.